Vaccinex
City of Rochester, New York, United States · Biotechnology, Healthcare, Health Care · 9 employees
Vaccinex, Inc. is a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, a SEMA4D blocking antibody, inhibits damaging inflammation and loss of homeostatic functions in the brain of patients with neurodegenerative diseases and promot
Funding history
- Series pre-seed — $200K — Sep 2024
- Series seed — $1.2M — Apr 2024
- Series seed — $1.8M — Apr 2024
- Series seed — $3.7M — Feb 2024
- Series seed — $2.0M — Sep 2020
Recent signals
- Nov 07, 2024: Vaccinex Partners with Amgen, Merck, and Other Companies to Utilize ActivMAb® Platform
- Oct 31, 2024: Launched Vaccinex Announces Positive Results for Pepinemab in Alzheimer's Disease Study at CTAD Conference in Madrid
- Sep 27, 2024: Raised $200K in Series pre-seed
- Apr 12, 2024: Raised $1.2M in Series seed
- Apr 12, 2024: Raised $1.8M in Series seed
- Feb 08, 2024: Raised $3.7M in Series seed
- Sep 16, 2020: Raised $2.0M in Series seed
- Aug 11, 2020: Raised $8.0M
See plans & pricing → Track Vaccinex’s funding, hiring, and signals — with verified contacts — on Fundz.